Skip to content

Study · Not a test of the peptide alone · 1991

1 result

Solid-phase synthesis of biologically active fragment 29-111 of rat prothymosin alpha.

Abiko T, Sekino H

Biotechnology and applied biochemistry1 Jun 1991

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneEx vivo tissueActivity measurement

    In peripheral blood from uremic patients, synthetic prothymosin alpha fragment 29-111 increased E-rosette-forming lymphocytes, and its restoring effect was greater than that of synthetic thymosin alpha‑1.

    In plain wordsIn lab tests on blood cells, the prothymosin fragment raised immune cell counts more than thymosin alpha‑1 did.

    Outcome
    IncreaseE-rosette-forming lymphocytes with fragment 29-111 versus thymosin alpha 1
    Study

    humann: not reported in source

    Peripheral blood from uremic patients
    Comparator
    Synthetic thymosin alpha 1
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    An increase of E-rosette-forming lymphocytes was obtained after incubation of peripheral blood from uremic patients with the synthetic prothymosin alpha fragment 29-111. The restoring effect of the synthetic prothymosin alpha fragment 29-111 was greater than that of our synthetic thymosin alpha 1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.